Why different PDB IDs for the same dysregulated protein can lead to inconsistent in-silico predictions and preclinical results

Accurate protein modeling and prediction are fundamental to contemporary drug discovery, with structural databases such as the Protein Data Bank (PDB) serving as indispensable resources. The existence of multiple PDB ID entries for identical proteins, however, presents significant computational challenges arising from structural variations induced by experimental conditions, ligand binding states, and mutational differences. This study presents a case study examination on how structural variability within PDB ID entries affects molecular docking accuracy. Our analysis reveals systematic deficiencies in current structural bioinformatics practices, particularly the absence of standardized frameworks for evaluating structural quality and biological relevance. Researchers inadvertently introduce selection bias when choosing protein structures, resulting in cascading effects on experimental outcomes and validation procedures. Therefore, to enhanced prediction reliability, strategic integration of multiple validation approaches is needed through implementation of stereochemical validation tools, molecular dynamics simulations, prioritization of high-resolution entries, incorporation of biologically relevant cofactor environments, and systematic cross-referencing between experimental binding states and computational models. Additionally, improved receptor flexibility modeling through ensemble and induced-fit docking (IFD) techniques will significantly enhances predictive accuracy. With this insight, reproducible research in structural bioinformatics requires transparent disclosure of modeling methodologies, source structure selection criteria, and validation protocols.